Targeted Therapy
Approved for: NSCLC
Biomarker: ALK

Alectinib (Alecensa) is a FDA-approved Targeted Therapy for Non-small cell lung cancer (NSCLC) that is ALK positive and has metastasized (spread to other parts of the body).

.